Disclaimer

The alfapump® system is currently not approved in Canada for commercial use. DSR® therapy is still in development and is currently not approved in the United States or Canada. Any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. Sequana Medical makes no claims of safety or effectiveness of the DSR® therapy in the U.S. or Canada. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe, the United States or Canada.

Day

December 17, 2020
Gent, BELGIË – 17 december 2020 – Sequana Medical NV (Euronext Brussels: SEQUA), een vernieuwer in de behandeling van vochtophoping in leveraandoeningen, maligne ascites en hartfalen, kondigt vandaag aan dat het management team zal deelnemen aan twee virtuele investor events, die parallel lopen met de 39e Jaarlijkse JP Morgan Healthcare Conference.   10th Annual LifeSci...
Read More

PERSBERICHTEN

INSCHRIJVEN OP ONZE PERSBERICHTEN